ATE404692T1 - Screening-verfahren zur identifizierung von tau- protein modulierenden substanzen. - Google Patents

Screening-verfahren zur identifizierung von tau- protein modulierenden substanzen.

Info

Publication number
ATE404692T1
ATE404692T1 AT04743090T AT04743090T ATE404692T1 AT E404692 T1 ATE404692 T1 AT E404692T1 AT 04743090 T AT04743090 T AT 04743090T AT 04743090 T AT04743090 T AT 04743090T AT E404692 T1 ATE404692 T1 AT E404692T1
Authority
AT
Austria
Prior art keywords
tau protein
fyn
candidate
phosphatase
site
Prior art date
Application number
AT04743090T
Other languages
English (en)
Inventor
Brian Anderton
Diane Hanger
Malcolm Ward
Helen Byers
Original Assignee
Proteome Sciences Plc
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteome Sciences Plc, King S College London filed Critical Proteome Sciences Plc
Application granted granted Critical
Publication of ATE404692T1 publication Critical patent/ATE404692T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
AT04743090T 2003-06-25 2004-06-25 Screening-verfahren zur identifizierung von tau- protein modulierenden substanzen. ATE404692T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0314943.2A GB0314943D0 (en) 2003-06-25 2003-06-25 Screening methods

Publications (1)

Publication Number Publication Date
ATE404692T1 true ATE404692T1 (de) 2008-08-15

Family

ID=27637418

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04743090T ATE404692T1 (de) 2003-06-25 2004-06-25 Screening-verfahren zur identifizierung von tau- protein modulierenden substanzen.

Country Status (11)

Country Link
US (2) US8822171B1 (de)
EP (1) EP1636375B1 (de)
JP (2) JP5688747B2 (de)
AT (1) ATE404692T1 (de)
AU (1) AU2004252273B2 (de)
CA (2) CA2527437C (de)
DE (1) DE602004015791D1 (de)
DK (1) DK1636375T3 (de)
ES (1) ES2313032T3 (de)
GB (1) GB0314943D0 (de)
WO (1) WO2005001114A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods
AU2005253776B8 (en) * 2004-06-21 2012-02-02 King's College London Screening methods using c-Abl, Fyn and Syk in combination with tau protein
JP4522910B2 (ja) * 2005-05-30 2010-08-11 株式会社日立ハイテクノロジーズ 質量分析方法及び質量分析装置
JP5518479B2 (ja) * 2006-10-25 2014-06-11 ザ ロックフェラー ユニヴァーシティ Aβ関連障害の処置のための方法およびその組成物
US20110294144A1 (en) * 2008-02-12 2011-12-01 Kenichi Noguchi Screening method
GB0903913D0 (en) * 2009-03-06 2009-04-22 Medical Res Council Compositions and methods
EP2651405A2 (de) 2010-12-14 2013-10-23 Electrophoretics Limited Casein-kinase-1 (ck1)-inhibitoren
WO2014055413A2 (en) * 2012-10-02 2014-04-10 Bloodcenter Research Foundation A method of providing cellular therapy using modified natural killer cells or t lymphocytes
RU2016132574A (ru) 2014-01-09 2018-02-12 Интра-Селлулар Терапиз, Инк. Органические соединения
US10924675B2 (en) 2016-03-11 2021-02-16 Apple Inc. Optical image stabilization with voice coil motor for moving image sensor
US11956544B2 (en) 2016-03-11 2024-04-09 Apple Inc. Optical image stabilization with voice coil motor for moving image sensor
US10437023B2 (en) 2016-03-28 2019-10-08 Apple Inc. Folded lens system with three refractive lenses
US10890734B1 (en) 2017-03-29 2021-01-12 Apple Inc. Camera actuator for lens and sensor shifting
US10863094B2 (en) 2017-07-17 2020-12-08 Apple Inc. Camera with image sensor shifting
US11122205B1 (en) 2018-09-14 2021-09-14 Apple Inc. Camera actuator assembly with sensor shift flexure arrangement
US11575835B2 (en) 2020-09-24 2023-02-07 Apple Inc. Multi-axis image sensor shifting system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
WO1995019178A1 (en) 1994-01-13 1995-07-20 Research Foundation For Mental Hygiene, Inc. Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
US6593512B1 (en) * 1999-03-03 2003-07-15 Cognosci, Inc. Transgenic mouse expressing human tau gene
AU6722300A (en) * 1999-08-31 2001-03-26 Ramot University Authority For Applied Research And Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
US20020172990A1 (en) * 2002-02-19 2002-11-21 Thomas Curran Cyclin dependent kinase 5 phosphorylation of disabled 1 protein
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods

Also Published As

Publication number Publication date
JP5688747B2 (ja) 2015-03-25
ES2313032T3 (es) 2009-03-01
CA2527437A1 (en) 2005-01-06
CA2848433C (en) 2017-01-10
AU2004252273A1 (en) 2005-01-06
GB0314943D0 (en) 2003-07-30
AU2004252273B2 (en) 2011-04-28
DK1636375T3 (da) 2008-12-15
CA2848433A1 (en) 2005-01-06
JP2007527210A (ja) 2007-09-27
EP1636375A2 (de) 2006-03-22
WO2005001114A3 (en) 2005-03-31
US20150051097A1 (en) 2015-02-19
DE602004015791D1 (de) 2008-09-25
CA2527437C (en) 2016-08-02
EP1636375B1 (de) 2008-08-13
US8822171B1 (en) 2014-09-02
WO2005001114A2 (en) 2005-01-06
JP2012045002A (ja) 2012-03-08

Similar Documents

Publication Publication Date Title
ATE404692T1 (de) Screening-verfahren zur identifizierung von tau- protein modulierenden substanzen.
ATE468407T1 (de) Verfahren zur identifizierung von proteinen mit stärkephosphorylierender enzymatischer aktivität
DE60041355D1 (de) Verfahren zur detektion von erkrankungen
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
DE60328885D1 (de) Verfahren zur Beurteilung eines Krankheitzustandes mittels Nachweis von partikel- und nicht partikelgebundenen Nukleinsäuren in Blutplasma und -serum
ATE417274T1 (de) Verfahren zur identifizierung von mit zap-70 wechselwirkenden molekülen und zur zap-70- reinigung
ATE416385T1 (de) Verfahren zur quantifizierung der phosphokinaseaktivität auf proteinen
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
ATE431854T1 (de) Auf bio-barcodes beruhender nachweis von zielanalyten
ATE497164T1 (de) Testverfahren zur messung der phosphorylierung
ATE324462T1 (de) Assays zur detektierung von modulatoren der cytoskeletalen funktion
DE60324207D1 (de) Verfahren zur identifizierung und/oder validierung von rezeptortyrosinkinase-inhibitoren
ATE345397T1 (de) Verfahren zur isolierung von bakterien aus biologischen proben
ATE414701T1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
ATE533055T1 (de) Verfahren zum screenen mithilfe von konformationsempfindlichen peptiden
ATE238551T1 (de) Homogene nachweisverfahren zur bestimmung der phosphorylierungsaktivitäten von biologischem material
ATE221657T1 (de) Entstörung durch rheumafaktoren
EP1138781A3 (de) Methode zur Quantifizierung der Bindeaktivität von DNA-bindenden Proteinen
DE60010323D1 (de) Fluoreszenzkorrelationsspektroskopie zur identifizierung von verbindung-ziel-bindung
DE602004011228D1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
DE602005018808D1 (de) Odifizierung der supercoil-topologie von nukleinsäuren sowie modulatoren
DE60331669D1 (de) Identifikation von Arzneimittel gegen Mykobakterien
ATE359513T1 (de) Hochdurchsatzscreening von verbindungen für biologische wirksamkeit
ATE426807T1 (de) Proteomanalyse verfahren zum drogen vergleich
ATE430317T1 (de) Enzymatische messung von imatinib-mesylat

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1636375

Country of ref document: EP